Cancer will replace diabetes/heart disease as the dominant disease category in the upcoming list of Part D drugs selected for the Medicare price negotiation process, researchers Sean Sullivan and Emma Cousin from the University of Washington and Inmaculada Hernandez of the University of California San Diego predict in a new analysis.
Key Takeaways
-
As many as six oral cancer drugs could be selected for Medicare price negotiation in the next round, which begins in 2025 for prices going into effect in 2027, according to a new analysis by researchers at the University of Washington and the University of California San Diego.
Using the selection criteria laid out in the Inflation Reduction Act, the researchers produced a list of 13 drugs they...
